核型正常急性髓系白血病中miRNA-181a的表达特征及预后意义
研究检测120例初诊原发核型正常急性髓系白血病(CN-AML)患者骨髓单个核细胞miRNA-181a表达,并分析其与基因突变、临床指标及预后的关系。结果显示miRNA-181a高表达组中位总生存和无复发生存均较低表达组更长,高表达是影响CN-AML患者预后的独立因素。
要点
- miRNA-181a高表达组中位OS 25.0个月,低表达组15.0个月(P<0.05)。
- miRNA-181a高表达组中位RFS 21.4个月,低表达组11.2个月(P<0.001)。
- 多因素Cox回归显示miRNA-181a高表达是CN-AML预后的独立因素(HR=2.219)。
核心结论
- miRNA-181a高表达是独立于临床指标和高频基因突变的预后良好标志物,其表达水平可作为CN-AML预后的重要指标。
研究设计与样本
- 采用实时荧光定量PCR法检测120例初诊原发CN-AML患者骨髓单个核细胞miRNA-181a的表达水平。
- PCR后采用直接测序方法检测IDH1、IDH2、NPM1、FLT3-ITD、DNMT3A和CEBPα突变。
- 分析miRNA-181a表达与基因突变、其他临床指标和预后的关系。
主要发现
- miRNA-181a高表达组和低表达组患者中位总生存(OS)时间分别为25.0个月和15.0个月(P<0.05)。
- miRNA-181a高表达组和低表达组患者中位无复发生存(RFS)时间分别为21.4个月和11.2个月(P<0.001)。
- miRNA-181a高表达组患者血红蛋白水平、完全缓解率、NPM1野生型比例均较低表达组高,差异有统计学意义(P值均<0.05)。
- Cox回归模型多因素分析显示,miRNA-181a高表达是影响CN-AML患者预后的独立因素(HR=2.219,95%CI 1.601~2.432,P=0.018)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To study the expression of miRNA-181a in acute myeloid leukemia (AML) patients with normal karyotype to probe its prognosis significance. Methods: The expression level of miRNA-181a in bone marrow mononuclear cells of 120 de novo AML patients with normal karyotype was detected by real time fluorescence quantitative PCR. The direct sequencing method was used to detect IDH1, IDH2, NPM1, FLT3-ITD, DNMT3A and CEBPα mutations in CN-AML patients after PCR. The relationship between miRNA-181a expression and gene mutation, the clinical parameters and prognosis were analyzed. Results: The rates of overall surviva1 (OS) in high expression and low expression groups were 25.0 months and 15.0 months, respectively (P<0.05) . Relapse free survival (RFS) in high expression and low expression groups were 21.4 months and 11.2 months, respectively (P<0.05) . Significantly higher level hemoglobin, complete remission rate and proportion of wild type NPM1 expression in the high expression of miRNA-181a group were observed when compared with the lower expression of miRNA-181a group (P<0.05) . Multivariate Cox regression analysis showed miRNA-181a overexpression was an independent prognostic factor for CN-AML (HR=2.219, 95%CI 1.601~2.432, P=0.018) . Conclusion: Higher expression of miRNA-181a was a good prognostic factor independent of clinical parameters and high frequency gene mutations, which implicated that the miRNA-181a expression level could be used as an important prognostic indicator of AML patients with normal karyotype. 目的: 探讨核型正常急性髓系白血病(CN-AML)患者微RNA(miRNA)-181a的表达水平及其与预后的关系。 方法: 采用实时荧光定量PCR法检测120例初诊原发CN-AML患者骨髓单个核细胞miRNA-181a的表达水平,PCR后采用直接测序方法检测IDH1、IDH2、NPM1、FLT3-ITD、DNMT3A和CEBPα突变。分析miRNA-181a表达与基因突变、其他临床指标和预后的关系。 结果: miRNA-181a高表达组和低表达组患者中位总生存(OS)时间分别为25.0和15.0个月(P<0.05);中位无复发生存(RFS)时间分别为21.4和11.2个月(P<0.001)。miRNA-181a高表达组患者HGB水平、完全缓解率、NPM1野生型比例均较低表达组高,差异有统计学意义(P值均<0.05);用Cox回归模型多因素分析显示,miRNA-181a高表达是影响CN-AML患者预后的独立因素(HR=2.219,95%CI 1.601~2.432,P=0.018)。 结论: miRNA-181a高表达是独立于临床指标和高频基因突变的预后良好的标志物,miRNA-181a表达水平可作为CN-AML预后的重要指标。.
引用
- Zhuang XX, Ma QL, Wang HP, et al. [Expression characteristics and prognosis significance of miRNA-181a in acute myeloid leukemia with normal karyotype]. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 29166738. doi:10.3760/cma.j.issn.0253-2727.2017.10.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。